[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Novo-Nordisk](/topic/$nvo)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% +2%  
**1 Month**: XX% +7%  
**6 Months**: XX% -XX%  
**1 Year**: XX% -X%  
**1-Year High**: XX% on 2024-11-03  
**1-Year Low**: XX% on 2025-05-31  

**Most Supportive Themes**
- **Positive Clinical Trial Results and Wegovy's Cardiovascular Benefits:** (35%) Posts highlighting positive results from clinical trials for Novo Nordisk's drugs, particularly Wegovy, and its cardiovascular benefits.
- **Long-Term Growth Potential and Valuation:** (25%) Posts discussing the long-term growth potential of Novo Nordisk, especially in the obesity and diabetes markets, and its current valuation.
- **Expert Analysis and Recommendations:** (15%) Posts from analysts and financial experts recommending Novo Nordisk as a buy or highlighting its strengths.
  
**Most Critical Themes**
- **Competition and Market Share Concerns:** (20%)  Posts expressing concerns about increasing competition from other pharmaceutical companies, particularly Eli Lilly, and its impact on Novo Nordisk's market share.
- **Negative Guidance and Restructuring:** (5%)  Posts discussing the company's lowered sales and operating profit outlook, job cuts, and restructuring efforts.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| TikTok  | XXX      | X%  | XXXXXX  | XX% | XXXXX    | X%  |
| X       | XXXXXX   | XX% | XXXXXX  | XX% | XXXXXX   | XX% |
| Reddit  | XXX      | X%  | XXX     | X%  | XX       | X%  |
| YouTube | XXX      | X%  | XXXXX   | X%  | XX       | X%  |
|         |          |     |         |     |          |     |
| Total   | XXXXXX   | XX% | XXXXXXX | XX% | XXXXXXX  | XX% |